RxNews Recap for 03-25-11 Print E-mail
By BioMedReports.com Staff   
Friday, 25 March 2011 18:46
Below is a look at some of the headlines for companies that made news in the healthcare sector on March 25, 2011.

Biostar Pharmaceuticals (NASDAQ:BSPM) said Friday its fourth quarter profit more than tripled due to strong sales of its flagship hepatitis B drug, prompting a huge spike in the company's share price.

Callidus Software Inc. (NASDAQ: CALD), the leader in Sales Performance Management (SPM), announced today that it is a sponsor at the 9th Annual Sales Force Effectiveness Europe 2011 Conference, organized by eyeforpharma.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that Standard & Poor's (S&P) will add Edwards to the S&P 500 Index after the close of trading on Thursday, March 31, 2011.

First China Pharmaceutical Group, Inc. (OTCBB:FCPG)  is pleased to announce that a US $3,000,000 capital financing is well under way with US$2.7 million recently closed.

Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) today announced that it has completed patient enrollment in its U.S. Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter